Scientists Tried to Stop Aging by Blocking a Key Protein and the Results Were Unexpected

Scientists have long viewed the protein cGAS as a primary driver of inflammation, positioning it as a logical target for therapies intended to slow the biological clock. However, new research from the University of Rochester suggests that our understanding of this molecule was incomplete, revealing that suppressing the protein actually accelerates signs of aging rather than reversing them.

The study, published in the journal Nature Aging, highlights a paradoxical role for cGAS. While the protein is known to trigger immune responses when it identifies stray DNA, it also serves a critical, previously unappreciated function in maintaining genomic stability. When researchers removed cGAS from mouse models, the animals did not experience improved health. Instead, they suffered from increased frailty, higher levels of inflammation, and significantly shortened lifespans.

A Dual Role in Cellular Health

The cGAS-STING pathway has become a focal point in aging research because of its ability to initiate inflammation when it detects DNA within the cell’s cytoplasm—the area outside the nucleus. Typically, the presence of DNA in the cytoplasm is a hallmark of infection or cellular damage. By activating the STING protein, cGAS initiates an immune response. Because chronic, low-grade inflammation is a hallmark of aging and age-related illness, many scientists hypothesized that blocking this pathway would yield anti-aging benefits.

The University of Rochester team discovered that cGAS possesses a secondary, protective duty inside the cell nucleus. There, it helps maintain chromatin, the complex architecture that keeps DNA tightly packed. By stabilizing this structure, cGAS prevents the expression of retrotransposons known as LINE1s. These genetic elements can copy and paste themselves throughout the genome, and when they become active, they generate DNA that leaks into the cytoplasm, where the cell incorrectly identifies it as a viral threat.

“We thought that getting rid of cGAS would be beneficial because of its role in inflammation, but instead we found that it made animals age faster,” explains Vera Gorbunova, a professor of biology and codirector of the Rochester Aging Research (RoAR) Center.

Implications for Future Therapeutics

The findings challenge the current trajectory of drug development regarding inflammatory pathways. If scientists move forward with broad inhibitors that deactivate cGAS entirely, they risk stripping the body of a vital defense mechanism against genomic instability.

The research suggests that the goal for future medical interventions should be more nuanced. Rather than pursuing a universal “off switch,” investigators may need to develop targeted therapies that permit cGAS to continue its protective, stabilizing work within the nucleus while preventing its pro-inflammatory activity in the cytoplasm.

This discovery provides a clearer picture of why systemic inflammation increases as we age. As individuals grow older, the protective chromatin structure can degrade, allowing LINE1 elements to trigger the very immune cascades that contribute to cardiovascular disease, cancer, and neurodegeneration. Andrei Seluanov, a professor of biology and coauthor of the study, notes that the key to managing age-related decline lies in finding ways to mitigate persistent, harmful inflammation without undermining the cellular machinery that keeps our genome intact.